Scarica l'app Stockscreener
7.54
4.00%
0.29
Dopo l'orario di chiusura:
7.54
Kyntra Bio Inc Borsa (KYNB) Ultime notizie
KYNB Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating - Investing.com UK
Oppenheimer initiates Kyntra Bio stock coverage with outperform rating By Investing.com - Investing.com Canada
Enterprise value to revenue forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Enterprise value to EBITDA forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to earnings forward of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to book forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
KYNB Forecast — Price Target — Prediction for 2027 - TradingView
0IL8 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio, Inc. Actuals & Estimates (NASDAQ:KYNB) - TradingView
Enterprise value to EBIT forward of Kyntra Bio, Inc. – NASDAQ:KYNB - TradingView
Price to book forward of Kyntra Bio, Inc. – TRADEGATE:1FG0 - TradingView
1FG0 Forecast — Price Target — Prediction for 2027 - TradingView
Kyntra Bio Inc. (KYNB) Edges Higher on Above-Average Volume, Tests Key Resistance ZoneETH Profile - dars.gov.et
Kyntra Bio, Inc. Statistics – DUS:1FG0 - TradingView
Basic earnings per share (basic EPS) of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Net debt of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
Price to earnings ratio of Kyntra Bio, Inc. – DUS:1FG0 - TradingView
KYNTRA BIO (KYNB) director awarded 7,000 stock options at $7.13 strike - Stock Titan
KYNTRA BIO (KYNB) director Ho Maykin awarded 7,000 stock options at $7.13 - Stock Titan
Kyntra Bio (KYNB) director receives 7,000 options at $7.13 strike - Stock Titan
Kyntra Bio (KYNB) awards 7,000 stock options to director - Stock Titan
Kyntra Bio shareholders elect director and approve executive pay at annual meeting - Investing.com South Africa
Kyntra Bio, Inc. 8-K SEC Filing Details June 12, 2026 – Company Information, Address, and Stock Listing - Minichart
Kyntra Bio Shareholders Back Board, Pay and Auditor - TipRanks
Kyntra Bio (NASDAQ: KYNB) investors back board, pay and PwC auditor - Stock Titan
Kyntra Bio Inc. Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineLong-Term Guidance - newsline.com
Kyntra Bio Inc. Q1 2026 Earnings: Pre‑Revenue Biotech Posts Wider‑Than‑Expected Loss, Stock Gains 5.47% - newsline.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: EPS Misses Expectations, Shares Rally on Pipeline Progress - newsline.com
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Despite Positive Stock ReactionShort-Term Outlook - newsline.com
Kyntra Bio stock rises on roxadustat MDS trial data - Investing.com
Kyntra Bio (KYNB) Reveals Positive Trial Results for Anemia Trea - GuruFocus
Kyntra Bio stock rises on roxadustat MDS trial data By Investing.com - Investing.com Australia
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients By Investing.com - Investing.com Australia
Kyntra Bio Presents New Roxadustat Data On Improvements In Patients With Anemia Due To Lower-Risk Myelodysplastic Syndromes - TradingView
Kyntra Bio presents roxadustat data for anemia in LR-MDS patients - Investing.com
Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes - The Manila Times
Kyntra Bio Presents New Roxadustat Data on Improvements in - GlobeNewswire
Kyntra Bio Receives Final $4 Million Payment Under 2025 Share Purchase Deal With AstraZeneca - Moomoo
Kyntra Bio Receives Final Payment for China Divestiture - TipRanks
Kyntra Bio (KYNB) CEO updates holdings after RSU tax-withholding event - Stock Titan
[Form 4] KYNTRA BIO, INC. Insider Trading Activity - Stock Titan
Kyntra Bio receives final $4.0M holdback from AstraZeneca, completes China sale proceeds - TradingView
Kyntra Bio (NASDAQ: FGEN) completes $220M China sale payments - Stock Titan
KYNB Initiated by Rodman & Renshaw -- Rating Set to Buy - GuruFocus
Rodman & Renshaw initiates Kyntra Bio stock with buy rating By Investing.com - Investing.com Nigeria
Rodman & Renshaw initiates Kyntra Bio stock with buy rating - Investing.com
Kyntra Bio Inc. (KYNB) Faces Selling Pressure as Stock Dips 1.47% – Key Levels in FocusFloat Adjusted Cap - newsline.com
KYNB Technical Analysis | Trend, Signals & Chart Patterns | KYNTRA BIO INC (NASDAQ:KYNB) - ChartMill
Kyntra Bio Inc. Q1 2026 Earnings: EPS Miss Amid Ongoing Pre-Revenue Development PhaseEarnings Manipulation Risk - newsline.com
Kyntra Bio Inc. Q1 2026 Earnings: Wider-Than-Expected Loss Reinforces Pre-Revenue ChallengesHigh Growth Earnings - The Legal Advocate
KYNBKyntra Bio Inc Stock Price and Quote - Finviz
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Push - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Wider-than-Expected Loss Fails to Dampen Investor SentimentProfit Margin Analysis - The Legal Advocate
Kyntra Bio Inc. (KYNB) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Stock Edges HigherEPS Growth Rate - The Legal Advocate
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):